News Feed Opinion Career Insight Dialogues Blog
Positive Societies Drugs Stories History
December, 2023
December 2023
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
María Natalia Gandur Quiroga: After a successful ESMO 23, ADC continues to shine
Photo taken from María Natalia Gandur Quiroga/LinkedIn
Nov 4, 2023, 00:25

María Natalia Gandur Quiroga: After a successful ESMO 23, ADC continues to shine

María Natalia Gandur Quiroga shared a post on X/Twitter:

“After a successful ESMO 23, ADC continues to shine. A critical question for the future of ADC: Who will be their ideal partner?
ADCs are vital anticancer drugs for solid and hematological malignancies.

  • Regulatory approvals obtained mainly as single agents, limited success in combinations.
  • Ideal partners enhance effects without overlapping toxicities.
  • Active forerunners: antiangiogenic compounds, HER2-targeting drugs, DNA-damage response agents, and immune checkpoint inhibitors (ICIs).
  • Next-gen ADCs: tumor-specific targets, improved conjugation tech, novel linkers and payloads.
  • Clinical trials: patient preselection crucial based on target expression, response relationship, and safety considerations.
  • Trial designs: robust hypotheses for combinations, Phase 1 combinatorial evaluations, dose escalation with adaptive strategies.
  • Challenges: nonspecific target expression, overlapping toxicities, lack of efficacy in distinct tumor clones, resistance mechanisms.
  • Solutions: optimizing ADC properties, patient selection based on predictive biomarkers, preclinical and window-of-opportunity clinical testing for rational combinations.”

For more information click here.
Source: María Natalia Gandur Quiroga/Twitter.

Maria Natalia Gandur Quiroga is a Medical Oncologist and Chief of the Division of Genitourinary Medical Oncology at the Instituto de Oncología Ángel H. Roffo in Buenos Aires, Argentina. She is a Professor of Medicine at the University of Buenos Aires at the Oncologists Post Graduates Studies. Her research focuses on clinical trials with aims to improve the treatment of patients with urologic tumors.  She is an active member of the European Association for Cancer Research, Argentinian Medical Association and American Society of Clinical Oncology.

ADC cancer Drugs ESMO 2023 María Natalia Gandur Quiroga OncoDaily Oncology
Insight
Dec 9, 2023, 04:44
President Biden: It's good for the millions of Americans who can't afford their medications
Blog
Dec 9, 2023, 00:38
Thomas Hofmarcher: This is what a great panel discussion looks like!
Blog
Dec 9, 2023, 00:32
Zhiheng Xu: It's not just about how much statistics you know
Blog
Dec 9, 2023, 00:23
Priscilla Chan: Mark and I wrote our annual letter this year about how some of our earliest bets in science are letting us take advantage of this moment in AI
Blog
Dec 9, 2023, 00:18
David Fajgenbaum: 1 in 10 of us will develop a disease with no treatments
Career
Dec 8, 2023, 17:54
Dana-Farber News congratulates Sara Tolaney on receiving the Susan G. Komen 2023 Rising Star Researcher Award
Drugs
Dec 8, 2023, 17:50
Pure Biologics to test molecule PBA-0405 in project PB004 in a Phase 0 clinical trial in patients with solid tumors - The Antibody Society
Drugs
Dec 8, 2023, 17:46
Earle Burgess: Interested in new treatments being developed for advanced (urothelial) bladder cancer?
Insight
Dec 8, 2023, 17:40
Ibrahim Halil Sahin: A common question I received after my tweet on the PEGASUS trial...
Career
Dec 8, 2023, 17:35
Timothy M. Pawlik: Excited to announce Samilia Obeng-Gyasi as THE inaugural Endowed Surgical Professor in Health Equity
Insight
Dec 8, 2023, 17:32
Daniel Stover: Tumor genomic testing (TGT) is standard for MBC patients
Blog
Dec 8, 2023, 17:27
Tedros Adhanom Ghebreyesus: Gaza cannot afford to lose any more hospitals…
Insight
Positive
Societies
Career